In an effort to curb the spread of COVID-19 while a targeted vaccine is still in development, researchers at the University of Exeter in the U.K. have launched a clinical trial to see whether a tuberculosis vaccine first introduced in 1921 can offer temporary protection against the coronavirus. The study, known as BRACE, is based on evidence that the Bacillus Calmette-Guérin (BCG) vaccine may strengthen the body's general immune response, not just its defenses against tuberculosis.
The trial's principal investigator, Professor John Campbell of the University of Exeter Medical School, told the BBC that while the vaccine is unlikely to be specific to COVID-19, it could still be valuable. "Whilst we don't think [the protection] will be specific to COVID," he said, "it has the potential to buy several years of time for the COVID vaccines to come through and perhaps other treatments to be developed." This suggests the BCG vaccine could serve as a stopgap measure, reducing the number of infections while more precise vaccines and therapies are being finalized.
The idea of repurposing BCG for other diseases is not new. In a correspondence published in The Lancet in April, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, highlighted several studies showing the vaccine's broader benefits. For instance, a trial in Guinea-Bissau found that BCG reduced newborn deaths by 38 percent, largely by preventing pneumonia and sepsis. In South Africa, the vaccine was linked to a 73 percent reduction in respiratory infections. Even in the Netherlands, researchers observed that BCG helped fight yellow fever.
Why a century-old vaccine could matter now
BCG's long history and established safety profile make it an attractive candidate for rapid deployment. Unlike a new vaccine, which requires extensive testing and manufacturing scale-up, BCG is already produced globally and has been used in millions of people. If the BRACE trial shows even partial effectiveness against COVID-19, it could provide a low-cost, readily available tool to protect vulnerable populations while the world awaits a more targeted vaccine.
Dr. Ghebreyesus emphasized the potential impact, writing that "This would be an important tool in the response to Covid-19 and future pandemics." His comment underscores the broader implications of the research, which could inform how we handle not just the current crisis but also emerging infectious threats.
The BRACE trial is currently underway, with results expected in the coming months. While the scientific community remains cautious about overstating the vaccine's potential, the urgency of the pandemic has prompted a global push to explore every possible avenue. If successful, this 99-year-old vaccine could become an unexpected ally in the fight against a 21st-century virus.





